The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, attendees will learn how to increase the chances of success in brain chancer drug development with the use of modern trial infrastructure, advanced imaging and select imaging biomarkers that go beyond conventional radiographic assessments. The featured speakers will discuss advanced imaging strategies in global multi-center clinical trials and accelerating drug development through efficient central imaging data management and centralized review.

Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments. This is where non-invasive methods are needed to enhance the understanding of complex neuro-pathologies.

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials are a challenge.

Advanced cancer therapies, such as WPD’s Berubicin treatment, often lead to pseudo-progression, a local tissue reaction resulting from immune cell infiltration, causing inflammation, tumor necrosis and edema which are often misinterpreted as tumor growth on traditional MRIs.

Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments. This is where non-invasive methods are needed to enhance the understanding of complex neuro-pathologies.

Novel imaging strategies and artificial intelligence (‘AI’) driven imaging biomarkers can advance neuro-oncology clinical trials by providing deep analysis of disease progression and treatment response. They are most efficiently integrated in clinical trials when implemented using a cloud-platform, such as IAG’s DYNAMIKA, that combines central review of standard radiographic endpoints, such as Response Assessment in Neuro-Oncology (‘RANO’), as well as advanced imaging endpoints in a cost and time-efficient fashion.

Join Mariusz Olejniczak, CEO at WDP Pharmaceuticals and Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer at IAG, Image Analysis Group in a live webinar on Thursday, April 15, 2021 at 1pm EDT to learn more about Berubicin and how the development of novel brain cancer therapies can be advanced with the use of AI and efficient imaging data management.

For more information, or to register for this event, visit The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website